Shoulder Innovations, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SI research report →
Range $27 – $28
Price Chart
About the company
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system.
- CEO
- Robert Joseph Ball
- IPO
- 2025
- Employees
- 74
- HQ
- Grand Rapids, MI, US
Get TickerSpark's AI analysis on SI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $421.58M
- P/E
- -12.35
- PEG
- -3.26
- P/S
- 6.49
- P/B
- 3.52
- EV/EBITDA
- -13.22
- Div Yield
- 0.00%
- Gross Margin
- 77.82%
- Op Margin
- -54.44%
- Net Margin
- -51.72%
- ROE
- -25.83%
- ROIC
- -26.33%
Latest fiscal year · YoY change
- Revenue
- $47.32M+49.6%
- Gross Profit
- $36.20M+48.7%
- Op Income
- $-26,297,000
- Net Income
- $-40,359,000-158.4%
- EPS
- $-1.96-154.5%
- OCF Growth
- -102.3%
- FCF Growth
- -98.4%
- 52W High
- $24.60
- 52W Low
- $12.00
- 50D MA
- $19.16
- 200D MA
- $17.51
- Beta
- -1.77
- RSI (14)
- 50
- Avg Volume
- 120.15K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Shoulder Innovations posted another strong growth quarter, raised full-year revenue guidance, and highlighted continued surgeon adoption, margin improvement, and an expanding product pipeline.· November 5, 2026
- Q3 net revenue was $16.2 million, up 38% year over year, with gross margin of 78.5% versus 76.2% last year.
- Management raised full-year 2026 revenue guidance to $68 million-$70 million, from $67 million-$69 million previously, implying 44%-48% growth.
- Implant volume in core contender and prospect customers rose about 34% year over year to 2,126 units, driven by new surgeon additions and higher utilization.
- The company launched InSet Go in October and received FDA clearance for and launched the N-22 humeral head; management said surgeon response has been positive.
- Cash equivalents and marketable securities were $92.3 million at quarter-end, and management said cash burn improved again in Q3 and remains compatible with reaching cash flow break-even with cash on hand.
Third-quarter 2026 net revenue was $16.2 million, up 38% from $11.8 million in the prior-year period. Gross margin was 78.5%, compared with 76.2% last year. Net loss was $7.0 million, versus a loss of $8.7 million a year ago, and Adjusted EBITDA loss was $5.5 million, versus a loss of $7.5 million. SG&A was $17.1 million, up from $15.1 million, and R&D was $3.2 million, up from $1.5 million. Cash equivalents and marketable securities were $92.3 million as of September 30, 2026. For 2026, management now expects net revenue of $68 million-$70 million, representing 44%-48% growth, up from prior guidance of $67 million-$69 million. Management expects similar gross margins in Q4, SG&A as a percentage of revenue to increase in Q4 versus Q3, R&D as a percentage of revenue to remain relatively consistent in Q4 and begin moderating in 2027, and cash burn to moderately increase in Q4 due to added commercial and R&D investment.
Rob Ball framed the quarter as evidence that the company’s commercial model is durable, especially given normal orthopedic seasonality. He emphasized three priorities: adding new surgeons, increasing utilization within the existing base, and broadening the product portfolio. His tone was constructive and confident, citing ahead-of-plan surgeon additions, strong feedback on new products, and a pipeline that he believes will support growth into 2027.
Jeff Points focused on the financial leverage and margin profile behind the growth. He noted gross margin of 78.5% was helped by higher ASPs and cost-reduction programs, while SG&A rose to $17.1 million from commercial headcount and variable selling expense, and R&D increased to $3.2 million due to product development, including robotics work. He also highlighted $92.3 million of cash and marketable securities, said cash burn improved again in Q3, and reiterated confidence in achieving cash flow break-even with cash on hand.
Analysts pressed for color on Q4 revenue assumptions, market health, pricing, and whether rep hiring is being helped by disruption at competitors. Management said guidance is based on continued surgeon additions and volume growth, and described recent momentum as strong but deliberately guided with a high degree of conviction. On market health, Rob Ball said he did not see data indicating a downturn or upturn, only normal seasonality; on pricing, he said new products can help price but ASC mix and pricing pressure there may offset some of that. He also said hiring success is being driven by culture, differentiated products, and strong talent, and that shoulder procedures have a deferral range but can become effectively non-elective when pain and sleep disruption become severe.
The bull case is that Shoulder Innovations is still growing rapidly while expanding both its surgeon base and per-surgeon utilization. Management also described multiple near- and medium-term product and partnership launches that could deepen attachment rates, support ASPs, and expand the addressable procedure mix. The company ended with strong cash reserves and said it believes it can keep investing while working toward cash flow break-even.
The main risks raised or acknowledged were seasonality, mix pressure from growing ASC exposure, and the fact that management still relies on a relatively small dataset to judge broader market health. SG&A and R&D are both rising, and cash burn is expected to increase modestly in Q4 as the company keeps investing. Several pipeline and partnership opportunities are still early, with meaningful revenue contribution from some initiatives not expected until 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.4%
- Shares Outstanding
- 20.92M
- Float Shares
- 18.28M
of shares held by institutions
75 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SI, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 3.90M | ▲ 221.21K |
| Blackrock, Inc. | 778.75K | ▲ 140.33K |
| Parkman Healthcare Partners LLC | 726.86K | ▲ 500.64K |
| Vanguard Capital Management LLC | 460.67K | ▲ 68.49K |
| Sectoral Asset Management Inc | 430.42K | ▲ 13 |
| Timessquare Capital Management, LLC | 350.73K | ▲ 52.52K |
| Driehaus Capital Management LLC | 298.39K | ▲ 44.63K |
| Geode Capital Management, LLC | 279.14K | ▲ 79.61K |
| Schonfeld Strategic Advisors LLC | 259.17K | ▲ 181.43K |
| Roubaix Capital, LLC | 229.94K | ▼ 25.34K |
| Vanguard Group Inc | 220.43K | ▲ 74.16K |
| Kcm Capital Inc | 180.00K | ▼ 120.00K |
Held by 125 ETFs
Biggest fund positions in SI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Ball Robert Joseph | other | 66,757 |
| Oct 30, 26 | Ball Robert Joseph | other | 29,639 |
| Oct 30, 26 | Ball Robert Joseph | other | 66,757 |
| Oct 5, 26 | Tansey Casey M | other | 733 |
| Oct 5, 26 | Sidow Kevin K. | other | 892 |
| Oct 5, 26 | Hykes Andrew | other | 669 |
| Oct 5, 26 | BUCKMAN PAUL | other | 1,275 |
| Sep 14, 26 | Ball Robert Joseph | other | 89,233 |
| Sep 14, 26 | Ball Robert Joseph | sell | 10,175 |
| Sep 14, 26 | Ball Robert Joseph | other | 89,233 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SI coverage
Recent articles, reports, and earnings notes.
No research on SI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SI report →Shoulder Innovations Doubles Customer Growth, Sets Sights on Surgical Robotics
marketbeat.com · Nov 13
Does Shoulder Innovations, Inc. (SI) Have the Potential to Rally 25.24% as Wall Street Analysts Expect?
zacks.com · Nov 13
Shoulder Innovations, Inc. (SI) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Here's Why Shoulder Innovations, Inc. (SI) is a Great Momentum Stock to Buy
zacks.com · Nov 10
What Shoulder Innovations (SI) Said on Its Q3 Earnings Call
marketbeat.com · Nov 8
Shoulder Innovations, Inc. (SI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Shoulder Innovations, Inc. (SI) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook
prnewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.